- Scientists demonstrate the potential of improving therapy with patient-derived tumor infiltrating lymphocytes (TILs) by applying RXi's novel sd-rxRNA compounds specific to PD-1. Targeting the PD-1/PD-L1 axis can enhance the ex vivo expansion rate and in vivo longevity and functionality of these T-cells and thereby have the potential to improve Adoptive Cell Therapy (ACT) outcomes in cancer patients.
- sd-rxRNA compounds are based on a proprietary therapeutic platform developed and owned by RXi Pharmaceuticals and are ideally suited to reprogram immune cells used in various forms of ACT.
PR Newswire
MARLBOROUGH, Mass., April 16, 2018